These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 31518175)
1. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175 [TBL] [Abstract][Full Text] [Related]
2. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. Guy H; Walder L; Fisher M Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768 [TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695 [TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000 [TBL] [Abstract][Full Text] [Related]
8. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273 [TBL] [Abstract][Full Text] [Related]
9. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Moore KN; Mirza MR; Matulonis UA Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193 [TBL] [Abstract][Full Text] [Related]
14. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Onstad M; Coleman RL; Westin SN Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474 [TBL] [Abstract][Full Text] [Related]
17. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572 [TBL] [Abstract][Full Text] [Related]
18. Niraparib: First Global Approval. Scott LJ Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297 [TBL] [Abstract][Full Text] [Related]